Tenaya Therapeutics Inc (TNYA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $79.59M
Last updated: Nov 17, 2026 at 11:05 AM ET
Tenaya Therapeutics Inc (TNYA) Financials: Revenue, Profit and Cash Flow
Tenaya Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$90.60M, operating cash flow was -$68.26M and free cash flow was -$68.88M. The quarter ended Sep 30, 2026 had revenue of $1.70M and net income of -$18.94M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $93.33M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Cost of revenue | $8.44M | $0 | $0 | $0 | $0 | $0 | $1.99M |
| Gross profit | -$8.44M | $0 | $0 | $0 | $0 | $0 | -$1.99M |
| Research and development | $68.61M | $86.74M | $98.04M | $94.54M | $54.39M | $31.10M | $23.15M |
| Operating income | -$93.33M | -$115.95M | -$131.19M | -$125.62M | -$72.81M | -$38.91M | -$27.71M |
| Net income | -$90.60M | -$111.13M | -$124.08M | -$123.67M | -$72.72M | -$38.40M | -$25.78M |
| EBITDA | -$82.16M | -$107.58M | -$122.14M | -$119.46M | -$69.74M | -$36.00M | -$25.72M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.70M | $1.11M | $225.00K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $17.66M |
| Gross profit | $1.70M | $1.11M | $225.00K | $3.95M | $0 | $0 | $0 | N/A | $0 | $0 | $0 | -$2.99M |
| Operating income | -$19.57M | -$44.09M | -$20.07M | -$20.77M | -$20.94M | -$24.08M | -$27.54M | -$24.65M | -$26.71M | -$30.82M | -$33.76M | -$31.45M |
| Net income | -$18.94M | -$43.39M | -$19.27M | -$20.18M | -$20.27M | -$23.28M | -$26.86M | -$23.84M | -$25.63M | -$29.43M | -$32.23M | -$29.93M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $3.02M by $97.53M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $146.92M | $119.94M | $170.51M | $278.94M | $314.19M | $148.16M | $38.00M |
| Current assets | $105.59M | $67.38M | $111.58M | $193.75M | $255.36M | $129.96M | $27.74M |
| Cash and equivalents | $100.55M | $4.32M | $45.68M | $95.27M | $38.13M | $128.53M | $23.87M |
| Total liabilities | $23.66M | $27.09M | $31.09M | $35.57M | $35.66M | $8.72M | $81.74M |
| Short-term debt | $3.02M | $2.78M | $4.32M | $4.01M | $1.99M | N/A | N/A |
| Shareholder equity | $123.27M | $92.85M | $139.42M | $243.38M | $278.53M | -$81.31M | -$43.74M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $76.68M | $93.54M | $135.07M | $146.92M | $104.98M | $122.15M | $143.95M | $119.94M | $140.58M | $163.19M | $184.90M | $170.51M |
| Total liabilities | $22.16M | $24.13M | $28.88M | $23.66M | $22.11M | $22.32M | $24.56M | $27.09M | $27.98M | $29.19M | $26.72M | $31.09M |
| Cash and equivalents | $66.80M | $78.08M | $80.89M | $100.55M | $56.31M | $62.67M | $53.77M | $4.32M | $8.23M | $58.13M | $59.30M | $45.68M |
| Shareholder equity | $54.52M | $69.41M | $106.19M | $123.27M | $82.87M | $99.83M | $119.40M | $92.85M | $112.60M | $134.00M | $158.18M | $139.42M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$68.26M | -$90.50M | -$102.07M | -$104.42M | -$60.81M | -$35.45M | -$24.10M |
| Capital expenditures | $618.00K | $1.02M | $1.24M | $20.63M | $25.12M | $9.76M | $2.93M |
| Free cash flow | -$68.88M | -$91.53M | -$103.31M | -$125.05M | -$85.93M | -$45.21M | -$27.02M |
| Share repurchases | N/A | $0 | $501.00K | $0 | $13.00K | $1.00K | N/A |
| Investing cash flow | $56.08M | $1.13M | $48.72M | $83.65M | -$238.56M | -$7.01M | -$5.58M |
| Financing cash flow | $108.41M | $47.75M | $4.05M | $77.77M | $208.97M | $147.27M | $30.51M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.68M | -$3.55M | -$19.23M | -$13.94M | -$15.60M | -$15.61M | -$23.11M | -$18.39M | -$19.84M | -$23.62M | -$28.66M | -$21.92M |
| Capital expenditures | N/A | $159.00K | $11.00K | $67.00K | $26.00K | $142.00K | $383.00K | $204.00K | $184.00K | $73.00K | $564.00K | $394.00K |
| Free cash flow | N/A | -$3.71M | -$19.25M | -$14.01M | -$15.63M | -$15.76M | -$23.50M | -$18.59M | -$20.02M | -$23.69M | -$29.22M | -$22.32M |
Frequently Asked Questions About TNYA
What is Tenaya Therapeutics' annual revenue?
Tenaya Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Tenaya Therapeutics profitable?
No. Tenaya Therapeutics reported net income of -$90.60M for the fiscal year ended Dec 31, 2025.
How much free cash flow does TNYA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$68.26M minus capital expenditures of $618.00K produced free cash flow of -$68.88M.
How much debt does Tenaya Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $3.02M and cash and equivalents of $100.55M.
TNYA pages: Overview, Earnings, Forecast, Financials, Competitors